← Back to Search

Other

HM15912 for Short Bowel Syndrome

Phase 2
Recruiting
Research Sponsored by Hanmi Pharmaceutical Company Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men or women, aged 18 years of age or older with Short Bowel Syndrome (SBS) resulting in intestinal failure at the time of signing the informed consent form (ICF) (or country's legal age of majority if the legal age is <18 years)
Be older than 18 years old
Must not have
History of colon cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up for 24 weeks
Awards & highlights

Summary

This trial will test a new drug for safety, how it is processed by the body, and how it affects people with a specific intestinal disorder.

Who is the study for?
Adults with Short Bowel Syndrome (SBS) who rely on parenteral nutrition or IV due to intestinal failure can join. They must have less than 200 cm of small bowel, stable for at least 6 months, and be able to consent. Those with a history of colon cancer, other cancers within the last 5 years (except certain skin cancers), or recent substance abuse cannot participate.Check my eligibility
What is being tested?
The trial is testing HM15912 against a placebo in adults with SBS-associated intestinal failure. It's randomized and double-blind, meaning neither participants nor researchers know who gets the real treatment versus placebo until after the results are collected.See study design
What are the potential side effects?
While specific side effects aren't listed here, typical ones may include reactions at injection sites, gastrointestinal symptoms, potential allergic responses, and changes in blood tests that monitor organ function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am an adult with Short Bowel Syndrome causing intestinal failure.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had colon cancer in the past.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~for 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and for 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events (AEs)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: HM15912 0.5 mg/kg, 1.0mg/kg, 1.5mg/kg ActiveExperimental Treatment1 Intervention
Group II: Matching PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Hanmi Pharmaceutical Company LimitedLead Sponsor
191 Previous Clinical Trials
61,308 Total Patients Enrolled

Media Library

HM15912 Active (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04775706 — Phase 2
Short Bowel Syndrome Research Study Groups: HM15912 0.5 mg/kg, 1.0mg/kg, 1.5mg/kg Active, Matching Placebo
Short Bowel Syndrome Clinical Trial 2023: HM15912 Active Highlights & Side Effects. Trial Name: NCT04775706 — Phase 2
HM15912 Active (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04775706 — Phase 2
~7 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top